GSK develops vaccines, specialty medicines, and consumer healthcare products distributed in numerous countries. Its vaccine portfolio covers prevention of shingles, respiratory syncytial virus, meningitis, and influenza, while pharmaceutical products target respiratory, oncology, and infectious disease areas. Healthcare systems and patients use these products for immunization and treatment of common and serious conditions.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 7,986 | — | 1,443 | — |
| Q3 2025 | 8,547 | — | 2,013 | — |
| Q4 2025 | 8,618 | — | 636 | — |
| Q1 2026 | 7,629 | — | 1,737 | — |
| Q2 2026 | 8,409 | 5.3% | 435 | -69.8% |
All markets — KeepWinning global stock screener
Other companies on NYSE: The Bank of New York Mellon Corporation (BNY), Agnico Eagle Mines Limited (AEM), ING Groep N.V. (ING), Quanta Services, Inc. (PWR), Duke Energy Corporation (DUK), General Dynamics Corporation (GD)